Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
NeoCore Technology Co., Ltd. is primarily engaged in the creation, manufacture, and distribution of biochips and advanced rapid nucleic acid hybridization devices. Their extensive product range features systems designed for food safety screening, human diagnostic arrays, agricultural analysis, and specific food examination arrays, in addition to a variety of laboratory instruments and DNA kits. The company further provides a suite of services, encompassing laboratory planning, design, and additional specialized support. Beyond its core biotech operations, NeoCore also participates in the wholesale and retail market for contact lenses. The firm, which was established in 1987 and is based in Tainan, Taiwan, underwent a name change in July 2023, transitioning from its former identity as DR. Chip Biotechnology Incorporation to its current name.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.